Relatlimab and nivolumab – July 2023

Relatlimab and nivolumab: Solution concentrate for I.V. infusion containing 80 mg relatlimab and 240 mg nivolumab in 20 mL vial; Opdualag® - March 2023- July 2023 PBAC meetings

Brand names:
- Opdualag®
Pharmaceutical Company:
- Bristol-Myers Squibb Australia Pty Ltd
Condition/Indication: Melanoma
Meeting Date: July 2023
Public Summary Document (PSD) March 2023 July 2023 PBAC Meetings - (PDF 1.1MB)
Public Summary Document (PSD) March 2023 July 2023 PBAC Meetings - (Word 796KB)

Related Public Summary Documents

Relatlimab and nivolumab – March 2023

Last updated

27 October 2023